Ann Intern Med

1. QASEEM A, Obley AJ, Harrod CS, Wilt TJ, et al
   Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians.
   Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05485.
   

   >> Share

   
   
2. MOSER ITK, Dobrescu AI, Sommer I, Goeschl S, et al
   Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
   Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05536.
   

   >> Share

   
   
3. SACKS HS
   In older adults, high- vs. standard-dose influenza vaccine reduced hospitalization for influenza or pneumonia in those with CKD.
   Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-26-00324.
   

   >> Share

   
   
4. ANAND R, Glatt AE
   In healthy adults, a modified RNA vs. inactivated influenza vaccine reduced laboratory-confirmed influenza-like illness at >/=14 d.
   Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05681.
   

   >> Share

   
   

   
   BMC Pediatr

5. DADZIE LA, Ayisah C, Naabil DT, Adoboe IE, et al
   Determinants of incomplete childhood vaccination among children aged 0-23 months in Ghana: a facility-based cross-sectional study.
   BMC Pediatr. 2026 Mar 5. doi: 10.1186/s12887-026-06688.
   

   >> Share

   
   

   
   BMJ

6. TANNE JH
   US doctors withdraw from CDC vaccine committee, as RFK Jr appoints Bhattacharya as acting director.
   BMJ. 2026;392:s422.
   

   >> Share

   
   

   
   Clin Infect Dis

7. BRANCHE AR
   The Renaissance of RSV Diagnosis: How Understanding Burden can Inform Clinical Practice and Demonstrate the Benefit of Vaccines.
   Clin Infect Dis. 2026 Mar 6:ciag148. doi: 10.1093.
   

   >> Share

   
   
8. TAN CS, Anjan S, Ariza-Heredia EJ, Magana F, et al
   IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal RSV infections in immunocompromised patients.
   Clin Infect Dis. 2026 Mar 2:ciag117. doi: 10.1093.
   

   >> Share

   
   
9. NELLORE A, Goepfert P, Tan CS, Bajema K, et al
   IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19, Influenza, and RSV infections in immunocompromised patients.
   Clin Infect Dis. 2026 Mar 2:ciag114. doi: 10.1093.
   

   >> Share

   
   
10. GILMORE AC, Liang Y, Galbreath IM, Hobbs LK, et al
    Indirect Influenza Vaccine Effectiveness Under Randomized Conditions: A Systematic Review and Meta-Analysis.
    Clin Infect Dis. 2026 Feb 27:ciag138. doi: 10.1093.
    

    >> Share

    
    
11. GOEPFERT P, Katz MJ, Kaul D, Sharma T, et al
    IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal Influenza infections in immunocompromised patients.
    Clin Infect Dis. 2026 Feb 28:ciag116. doi: 10.1093.
    

    >> Share

    
    

    
    J Gen Virol

12. DISLERS A, Nilova O, Jansons J, Skrastina D, et al
    Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant.
    J Gen Virol. 2026;107:002240.
    

    >> Share

    
    

    
    J Immunol

13. SOUDANI N, Sidney J, Da Silva Antunes R, Case JB, et al
    Identification of immunodominant T cell epitopes in SARS-CoV-2 spike protein in Syrian hamsters.
    J Immunol. 2026;215:vkaf342.
    

    >> Share

    
    
14. WERNINGHAUS IC, Hinke DM, Katta K, Bogen B, et al
    A combinatorial DNA vaccine encoding APC-targeted, bivalent HA and NA antigens results in an improved influenza vaccine.
    J Immunol. 2026;215:vkaf378.
    

    >> Share

    
    

    
    J Infect Dis

15. KIM SY, Chen F, Kim WS, Ji HJ, et al
    Epitope-Based Multimeric Subunit Vaccine (ATOMSSUISpenta) Confers Broad Protection Against Streptococcus suis Infection.
    J Infect Dis. 2026 Mar 4:jiag131. doi: 10.1093.
    

    >> Share

    
    
16. ZHAO B, Zhang G, Wu J, Zhang W, et al
    Characterization of bronchiolitis and vaccine-induced enhanced respiratory disease in Syrian hamsters caused by respiratory syncytial virus infection.
    J Infect Dis. 2026 Mar 4:jiag136. doi: 10.1093.
    

    >> Share

    
    
17. JAYAWARDENA I, Dean NE, Witrick B, Litwin AH, et al
    2024-2025 COVID-19 mRNA Vaccine Effectiveness against Severe Disease.
    J Infect Dis. 2026 Mar 2:jiag137. doi: 10.1093.
    

    >> Share

    
    
18. VAN NGUYEN T, Tuan LA, Mai CTN, Ly LTK, et al
    Immunogenicity of HPV Vaccine in a High-Risk and Understudied Group: Female Sex Workers.
    J Infect Dis. 2026 Mar 1:jiag112. doi: 10.1093.
    

    >> Share

    
    
19. WANG L, Wang J, Hossain J, Cooper HC, et al
    Development and Characterization of Candidate Vaccine Viruses against High Pathogenicity Avian Influenza A(H5) Viruses for Rapid Pandemic Response.
    J Infect Dis. 2026 Feb 28:jiag132. doi: 10.1093.
    

    >> Share

    
    

    
    N Engl J Med

20. PUOPOLO KM
    Group B Streptococcal Disease.
    N Engl J Med. 2026;394:896-905.
    

    >> Share

    
    

    
    Nat Immunol

21. RELANO-RODRIGUEZ I, Du J, Lin ZJ, Kerwin M, et al
    Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates.
    Nat Immunol. 2026;27:586-599.
    

    >> Share

    
    

    
    Nat Med

22. KALLAS EG, Moreira JA, Patino EG, Braga PE, et al
    Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine.
    Nat Med. 2026 Mar 4. doi: 10.1038/s41591-026-04255.
    

    >> Share

    
    

    
    Pediatrics

23. TSUNG S, Zeng YB, Shah K, Asch SM, et al
    Cost-Effectiveness of Nirsevimab and Maternal RSVpreF Immunization Strategies in Low-Risk Infants.
    Pediatrics. 2026 Feb 20:e2025071558. doi: 10.1542/peds.2025-071558.
    

    >> Share

    
    

    
    PLoS One

24. FROLKE SC, Amirkhan KG, van der Bom-Baylon N, van Gils M, et al
    Class switching toward IgG4 six months after primary mRNA-based COVID-19 vaccination in kidney patients.
    PLoS One. 2026;21:e0336320.
    

    >> Share

    
    
25. SHOYEMI E, Aghedo OG, Obi C, Uwaoma CPK, et al
    Impact of demographic factors and HIV status on Hepatitis B vaccination adherence and completion rate among high-risk populations in Lagos State, Nigeria.
    PLoS One. 2026;21:e0321434.
    

    >> Share

    
    
26. BARTMANN C, Schmidt V, Morz M, Schwab M, et al
    Detection of spike protein in term placentas of COVID-19 vaccinated and/or SARS-CoV-2 infected women.
    PLoS One. 2026;21:e0344185.
    

    >> Share

    
    
27. AKTER S, Silva GVR, Oliveira JIN, Fulco UL, et al
    Immunoinformatics approach to engineer a multi-epitope vaccine against SdrG in skin commensal Staphylococcus epidermidis.
    PLoS One. 2026;21:e0327534.
    

    >> Share

    
    

    
    Vaccine

28. SATAKE M, Ito S, Sawano C, Scuffham P, et al
    Benefit-risk assessment of HPV vaccination programs in Australia, the United States, and Japan.
    Vaccine. 2026;78:128407.
    

    >> Share

    
    
29. LYONS AJ, Mhatre MM, Argenio K, Day S, et al
    Does human papillomavirus vaccination status differ by disability status in New York city public schools?
    Vaccine. 2026;78:128404.
    

    >> Share

    
    
30. RUIZ-PALACIOS GM, Cahn PE, Halperin SA, Wang R, et al
    Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection.
    Vaccine. 2026;78:128378.
    

    >> Share

    
    
31. MALIK S, Gu S, Sisskind J, Blatt S, et al
    Increasing HPV vaccine uptake using a "start at 9"strategy: A pilot program.
    Vaccine. 2026;78:128401.
    

    >> Share

    
    
32. ZHANG X, Vlasenko D, Hickman J, Buttery J, et al
    Evaluating online vaccination imagery: how misleading photos could impact safety.
    Vaccine. 2026;78:128398.
    

    >> Share

    
    
33. ZHOU Z, Lu X, Hu L, Zhu S, et al
    The safety and efficacy of in situ vaccine FOLactis for advanced hepatic malignancies.
    Vaccine. 2026;78:128377.
    

    >> Share

    
    
34. ANDRESEN JB, Graugaard C, Andersson M, Frisch M, et al
    Associations of adverse childhood experiences, sexual identity and sexual risk indicators with HPV vaccination uptake in Denmark - A nationwide epidemiological study.
    Vaccine. 2026;77:128367.
    

    >> Share

    
    
35. KRETCHY IA, Bonful HA, Opoku-Mireku M, Koduah A, et al
    Impact of caregivers' perceptions of malaria on their hesitancy toward childhood malaria vaccination.
    Vaccine. 2026;77:128389.
    

    >> Share

    
    
36. LIXIA H, Liangcheng X, Tian T, Dongmei Z, et al
    Prevalence of high-risk human papillomavirus among women with different HPV-vaccination status in Sichuan, China.
    Vaccine. 2026;77:128387.
    

    >> Share

    
    
37. DUFOUR L, Drouin J, Dray-Spira R, Le Vu S, et al
    Corrigendum to "Uptake of HPV vaccination and associated factors in France: a nationwide study from 2007 to 2023" [Vaccine 76 (2026) 128308].
    Vaccine. 2026;78:128402.
    

    >> Share

    
    
38. LEE S, Lee K, Yeo D, Jo H, et al
    Herpes zoster vaccination and the risk reduction of ophthalmic diseases: A nationwide emulated target trial in South Korea.
    Vaccine. 2026;78:128400.
    

    >> Share

    
    
39. WANG X, Patel C, Sharma K, Giles ML, et al
    Immunisation against vaccine-preventable diseases in individuals receiving immunosuppressive targeted therapies.
    Vaccine. 2026;78:128399.
    

    >> Share

    
    
40. MAUDONNET B, Tosetto M, Lima B, Silveira C, et al
    Information sources and COVID-19 vaccination in pregnancy: an exploratory survey from health facilities in Sao Paulo state, Brazil.
    Vaccine. 2026 Mar 3:128412. doi: 10.1016/j.vaccine.2026.128412.
    

    >> Share

    
    
41. DAVIS M, Shapiro C, Ciarlet M, Adams EM, et al
    A Phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60-85 years of age.
    Vaccine. 2026;77:128345.
    

    >> Share

    
    
42. NUZHATH T, Yang Y, Couture MC, Callaghan T, et al
    Modification and validation of the teen vaccine hesitancy scale toward vaccines for adolescents.
    Vaccine. 2026;77:128385.
    

    >> Share

    
    
43. ABOUISMAIL A, Sapayeva S, Erhardt EB, Maxwell R, et al
    Priming route and age at first vaccination shape prime and boost vaccine responses in rainbow trout (Oncorhynchus mykiss).
    Vaccine. 2026;78:128403.
    

    >> Share

    
    
44. KU CC, Rosello A, Walker J, Pouwels KB, et al
    The epidemiological effect and cost-effectiveness of expanded age eligibility for recombinant zoster vaccination in England.
    Vaccine. 2026;78:128405.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share